Tool for assessment of attitudes for applying a new approach in the decision-making process for reimbursement list in Bosnia and Herzegovina

References

• World Bank Group. Systematic country diagnostic update. Washington (DC): World Bank; 2020. Report No. 148573-BA. https://documents1.worldbank.org/curated/en/211081591353275875/pdf/Bosnia-and-Herzegovina-Systematic-Country-Diagnostic-Update.pdf.
   Google Scholar
• World Health Organization. Global excess deaths associated with COVID-19 (modelled estimates). Geneva: World Health Organization; 2023. https://www.who.int/data/sets/global-excess-deaths-associated-with-covid-19-modelled-estimates.
   Google Scholar
• World Bank. Air pollution management in Bosnia and Herzegovina. Washington (DC): World Bank; 2019. https://thedocs.worldbank.org/en/doc/571891579547481576-0080022020/original/AirQualityManagementinBosniaandHerzegovinaExecutiveSummaryeng.pdf.
   Google Scholar
• World Bank. Project Information Document (PID). Washington (DC): World Bank; 2019. Report No: PIDC28114 and No: PIDA29512. https://ewsdata.rightsindevelopment.org/files/documents/61/WB-P170861.pdf.
   Google Scholar
• Mujkic S, Marinkovic V. Critical appraisal of reimbursement list in Bosnia And Herzegovina. Front Pharmacol. 2017;8:1. doi: 10.3389/fphar.2017.00129.
   PubMed Web of Science ®Google Scholar
• Drummond MF. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ. 1992;1(2):85–9. doi: 10.1002/hec.4730010202.
   PubMedGoogle Scholar
• Simoens S. Use of economic evaluation in decision making. Drugs. 2010;70(15):1917–1926. doi: 10.2165/11538120-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Cellini SR, Kee JE. Cost-effectivness and cost-benefit analysis; handbook of practical program. 4th ed. San Francisco: Jossey Bass; 2015. p. 636–672.
   Google Scholar
• Robinson R. Cost-benefit analysis, economic evaluation and health care. BMJ. 1993;307(6909):924–926. doi: 10.1136/bmj.307.6909.924.
   PubMed Web of Science ®Google Scholar
• Coons SJ, Kaplan R. Cost-utility analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. 2nd ed. Cincinnati, Ohio: Harvey Whitney Books Company; 1996. p. 1–31.
   Google Scholar
• Drummond MF. Health economic models a question of balance – summary of an open discussion on the ­pharmacoeconomic evaluation of non-steroidal anti-inflammatory drugs. Rheumatology. 2000;39(suppl_2):29–32. doi: 10.1093/rheumatology/39.suppl_2.29.
   PubMedGoogle Scholar
• Bootman JL, Townsend RJ, McGhan WF. Introduction to phar macoeconomics. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 2nd ed. Cincinnati, Ohio: Harvey Whitney Books Company; 1996. p. 2–10.
   Google Scholar
• Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132(12):964–972. doi: 10.7326/0003-4819-132-12-200006200-00007.
   PubMed Web of Science ®Google Scholar
• Alsultan MS. The role of pharmacoeconomics in formulary decision making in different hospital in Riyadh, Saudi Arabia, Saudi. Saudi Pharm J. 2011;19(1):51–56. doi: 10.1016/j.jsps.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med. 1992;116(3):238–244. doi: 10.7326/0003-4819-116-3-238.
   PubMed Web of Science ®Google Scholar
• Health Care Act. Official Gazette of Federation BH No. 30/97;1997; with amendments No. 7/02, 2002; 70/08, 2008 and 109/12. 2012.
   Google Scholar
• The decision on the criteria for inclusion of medicinal products on the list of medicines on prescription reimbursed from Health Insurance Fund of the Republic of Srpska. Official Gazette of Republic of Srpska No. 2/10. 2010
   Google Scholar
• The decision on the methodology of determining the reference price of medicine from List of essential medicines for the needs of insured persons. The Health Insurance Fund of Brcko District BH, Official Gazette Brcko District BH, No. 52/11. 2011.
   Google Scholar
• Becirovic S, Marinkovic V, Lakic D. Assessment of the suitability of the delphi method for assessing the needs of pharmacoeconomic studies in the decision-making process. Ind J Pharm Edu Res. 2023;57(4):1232–1241. doi: 10.5530/ijper.57.4.147.
   Web of Science ®Google Scholar
• Diamond IR, Grant RC, Feldman B, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401–409. doi: 10.1016/j.jclinepi.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Andrade C, Menon V, Ameen S, et al. Designing and conducting knowledge, attitude, and practice surveys in psychiatry: practical guidance. Indian J Psychol Med. 2020;42(5):478–481. doi: 10.1177/0253717620946111.
   PubMedGoogle Scholar
• Turoff M. The design of a policy Delphi. Technol Forecast Soc Change. 1970;2(2):149–171. doi: 10.1016/0040-1625(70)90161-7.
   Web of Science ®Google Scholar
• Beiderbeck D, Frevel N, von der Gracht HA, et al. Preparing, conducting, and analyzing Delphi surveys: cross-disciplinary practices, new directions, and advancements. MethodsX. 2021;8:101401. doi: 10.1016/j.mex.2021.101401.
   PubMed Web of Science ®Google Scholar
• Gupta GU, Clarke RE. Theory and applications of the Delphi technique: a bibliography (1975-1994. Technol Forecast Soc Change. 1996;53(2):185–211. doi: 10.1016/S0040-1625(96)00094-7.
   Web of Science ®Google Scholar
• Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11(4):116–129. doi: 10.5662/wjm.v11.i4.116.
   PubMedGoogle Scholar
• Goetghebeur MM, Rindress D. Towards a European consensus on conducting and reporting health economic evaluations—A report from the ISPOR inaugural European conference. Value Health. 1999;2(4):281–287. doi: 10.1046/j.1524-4733.1999.24002.x.
   PubMedGoogle Scholar
• Rulebook on the procedure for adding. changing the status or deleting medicines from the list of medicines and the medicines program. “Official Gazette of Republi of Srpska”, No. 44/23. Article 6. 2023.
   Google Scholar
• Tachkov K, Savova A, Manova M, et al. Tackling reimbursement challenges to fair access to medicines – introduction to the topic. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):597–606. doi: 10.1080/14737167.2023.2203384.
   PubMed Web of Science ®Google Scholar
• Campbell SM, Shield T, Rogers A, et al. How do stakeholder groups vary in a Delphi technique about primary mental health care and what factors influence their ratings? Qual Saf Health Care. 2004;13(6):428–434. doi: 10.1136/qshc.2003.007815.
   PubMedGoogle Scholar
• Kaliner M, Amin A, Gehling R, et al. Impact of inhaled corticosteroid–induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi panel. P&R. 2005;30:573–601.
   Google Scholar